IgG antibody response to toxins A and B in patients with clostridium difficile infection

Clinical and Vaccine Immunology

Volumn 19, Issue 9, 2012, Pages 1552-1554

  Wullt, M ^a   Noren T ^b   Ljungh, A ^a   Akerlund T ^c  

^a LUND UNIVERSITY   (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITOXIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; IMMUNOGLOBULIN G ANTIBODY;

ADULT; AGE DISTRIBUTION; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; IMMUNOREACTIVITY; MALE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; RECURRENT DISEASE; RISK REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; ANTITOXINS; BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; ENTEROTOXINS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865966570     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00210-12     Document Type: Article

References (13)

1. Fenger RV, Linneberg A, Tvede M, Ostergaard C. 2009. Increasing seroprevalence of Clostridium difficile in an adult Danish general population. Epidemiol. Infect. 137:278-283.
2. Hu MY, et al. 2009. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 136:1206-1214.
3. Johnson S, Gerding DN, Janoff EN. 1992. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile. J. Infect. Dis. 166:1287-1294.
4. Kuehne SA, et al. 2010. The role of toxin A and toxin B in Clostridium difficile infection. Nature 467:711-713.
5. Kyne L, Warny M, Qamar A, Kelly CP. 2001. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357:189-193. (Pubitemid 32108091)
6. Kyne L, Warny M, Qamar A, Kelly CP. 2000. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 342:390-397. (Pubitemid 30084537)
7. Leav BA, et al. 2010. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 28:965-969.
8. Lowy I, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362:197-205.
9. Lyras D, et al. 2009. Toxin B is essential for virulence of Clostridium difficile. Nature 458:1176-1179.
10. Miyajima F, et al. 2011. Characterisation and carriage ratio of Clostridium difficile strains isolated from a community-dwelling elderly population in the United Kingdom. PLoS One 6:e22804. doi:10.1371/journal.pone. 0022804.
11. Viscidi R, et al. 1983. Serum antibody response to toxins A and B of Clostridium difficile. J. Infect. Dis. 148:93-100. (Pubitemid 13039317)
12. Warny M, Vaerman JP, Avesani V, Delmee M. 1994. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect. Immun. 62:384-389. (Pubitemid 24033753)
13. Wullt M, Odenholt I. 2004. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J. Antimicrob. Chemother. 54: 211-216. (Pubitemid 39028992)